(PharmaNewsWire.Com, May 26, 2017 ) Artificial Pancreas Devices System Market Research Report covers the present scenario and the growth prospects of the Artificial Pancreas Devices System Industry for 2016-2020. Artificial Pancreas Devices System Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Artificial Pancreas Devices System globally.
The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Following Companies Are Key Players of the Artificial Pancreas Devices System Market:
Medtronic Johnson & Johnson Insulet Tandem Diabetes Care Roche Other Prominent Vendors of Artificial Pancreas Devices System Market Are:
Beta Bionics Bigfoot Biomedical Cellnovo Dexcom Dose Safety “One trend in the market is increasing focus on closed loop systems. The increasing demand for APDS has driven the vendors to undertake extensive clinical trials toward product improvement, which are expected to have a positive impact on the market growth. The vendors such as Medtronic, Tandem Diabetes Care, Johnson & Johnson, and Insulet are currently focusing on the development of closed loop APDS, which is expected to propel the market growth owing to its potential advantages compared with existing APDS. The existing open loop APDS are low glucose suspend devices with semi-automation. As these systems are not integrated with advanced algorithms, the required user intervention is at a moderate level. On the contrary, closed-loop APDS are externally worn medical devices, which would enable individuals with type 1 diabetes to regulate blood glucose levels in a fully automated way with zero intervention required from the user.”
Ask Sample PDF of Artificial Pancreas Devices System Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10293235 According to the report, one driver in the market is increasing initiatives of research organizations fostering innovation in the market. The inspiring initiatives of research organizations such as JDRF enable the development of innovative products in the market. JDRF launched Artificial Pancreas Project in 2006 to foster the development of an artificial pancreas to help individuals with diabetes. Subsequently, JDRF collaborated with Medtronic in 2014 to develop a novel redundant sensor system, which is designed to boost the accuracy and reliability of APDS. The research also focused on the development of orthogonally redundant sensor system, which integrates an electrochemical sensor along with an optical sensor to provide accurate glucose values. Earlier, in June 2013, JDRF collaborated with BD for a three-year time period to develop a single optimized device that will handle multiple functions and avoid the need and complexities of dwelling catheters. Recently, the researchers at Harvard University started a program to identify and develop an effective treatment for type 1 diabetes. Subsequently, National Institutes of Health awarded $12.5 million to Harvard University in 2016 to undertake the field testing of two artificial pancreas algorithms. Such initiatives lead to the development of novel products as well as upgradation of existing systems.
Report also presents Geographical Segmentation analysis of Artificial Pancreas Devices System Market of Americas, APAC, EMEA region. Further, the report states that one challenge in the market is lack of smart control algorithms affecting the adoption rate of existing APDS. Though there are important developments in sensor and pump technology, the APDS is associated with the delays and inaccuracies in glucose sensing and insulin delivery. Such type of issues occurs when there is a disturbance in the routine system (such as uptake of meal), which triggers a rapid glucose rise that is significantly faster than the time required for insulin absorption and action. Thus, the vendors should focus on designing an APDS with smart sensors that consider a relatively slow response, giving time for the delays to fade before the next control action. In particular, to avoid hypoglycemia after a meal, the vendors has to design a moderately aggressive controller. This has driven the vendors to research on new control design, model predictive control (MPC) algorithm, which is based on a prediction of glucose dynamics using a model of the individual’s metabolic system. According to clinical studies, this design may be better for mitigation of time delays due to subcutaneous glucose sensing and insulin infusion. However, such smart algorithms have limited clinical evidence, and it may take few more years to develop an ideal algorithm.
Key questions answered in Artificial Pancreas Devices System market report:
What will the Artificial Pancreas Devices System market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving Artificial Pancreas Devices System market? What are the challenges to Artificial Pancreas Devices System market growth? Who are the key vendors in Artificial Pancreas Devices System market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
